| Shared Labs Grant – Establishing SRLs | Dr. Nadia Carlesso Ph.D., M.D. | Stem Cell-based Disease Modeling Shared Resource Laboratory |
$5,400,000 |
| Manufacturing Network Grant | Dr. Taby Ahsan | Scalable Expansion for Stem Cell-derived Therapies |
$1,998,174 |
| Foundation – Discovery Stage Research Projects | Qiong Annabel Wang | Utilizing Age-Specific Adipocyte Progenitor Cells for Cell Therapy in Older Patients |
$1,508,997 |
| Research Training Grant | Dr. Michael E. Barish Ph, D. | Research Training Program in Stem Cell Biology and Regenerative Medicine |
$5,234,731 |
| Clinical Trial Stage Projects | Prof. John A. Zaia | Evaluation and Characterization of SARS-CoV-2 Antibody in Convalescent Volunteer Plasma Donors for Potential Therapeutic Use |
$999,999 |
| Discovery Research Projects | Dr Jianhua Yu | Persistent Off-the-Shelf meACE2-CAR-IL-15 NK Cells Derived from CD34(+) Cord Blood Stem Cells to Prevent and Treat COVID-19 |
$150,000 |
| Alpha Stem Cell Clinics Network Expansion | Dr. Leo D Wang | The City of Hope Alpha Clinic: A roadmap for equitable and inclusive access to regenerative medicine therapies for all Californians |
$8,000,000 |
| Conference – The 2017 Alpha Stem Cell Clinic Annual Symposium | Prof. John A. Zaia | 2nd Annual Symposium of the CIRM Alpha Stem Cell Clinics Network
“Alpha Clinics – Making the Future a Reality for Stem Cell-Based Therapies” |
$79,287 |
| Conference – Manage The SPARK Annual Meeting | Dr. Paul M. Salvaterra | Manage the 2017 SPARK Annual Meeting |
$22,555 |
| Quest – Discovery Stage Research Projects | Dr Jianhua Yu | Reprogramming Somatic Cells into iPSCs Engineered with an Anti-PSCA CAR to Develop Allogeneic Off-the-Shelf Cell Therapy to Treat Pancreatic Cancer |
$2,263,500 |
| Quest – Discovery Stage Research Projects | Professor Yanhong Shi | Combating COVID-19 using human PSC-derived NK cells |
$249,998 |
| Quest – Discovery Stage Research Projects | Dr Saul J Priceman | Chimeric Antigen Receptor-Engineered Stem/Memory T Cells for the Treatment of Recurrent Ovarian Cancer |
$1,351,174 |
| Quest – Discovery Stage Research Projects | Dr. Saswati Chatterjee | Genome Editing of Sinusoidal Endothelial Stem Cells for Permanent Correction of Hemophilia A |
$2,182,193 |
| Quest – Discovery Stage Research Projects | Professor Yuan Chen | A Novel Approach to Eradicate Cancer Stem Cells |
$1,539,935 |
| Quest – Discovery Stage Research Projects | Markus Müschen | Lgr5-mediated self-renewal in B cell selection and leukemia-initiation |
$2,183,223 |
| Therapeutic Translational Research Projects | Lei Tian | Targeting pancreatic cancer with Allogeneic Off-the-Shelf PSCA-CAR NK cells |
$6,036,000 |
| Therapeutic Translational Research Projects | Dr Michael A. Caligiuri | Targeting multiple myeloma with BCMA-CAR NK cells expressing a GPRC5D-NKG2D bispecific antibody |
$6,036,001 |
| Therapeutic Translational Research Projects | Dr Jianhua Yu | Specific Targeting Hypoxia Metastatic Breast Tumor with Allogeneic Off-the-Shelf Anti-EGFR CAR NK Cells Expressing an ODD domain of HIF-1α |
$6,036,002 |
| Therapeutic Translational Research Projects | Prof. Karen S Aboody M.D. | Neural Stem cell-mediated oncolytic immunotherapy for ovarian cancer |
$2,873,262 |
| Therapeutic Translational Research Projects | Dr. Yanhong Shi Ph.D. | Process development for establishing an iPSC-based therapeutic candidate for Canavan disease |
$7,377,384 |
| SPARK | Dr. David Kong Ann | Train, Educate, and Accelerate Mastery of Stem cell research (TEAMS) program |
$508,476 |
| SPARK | Dr. Paul M. Salvaterra | SPARK Award Program in Stem Cell Biology for California High School Students |
$241,080 |
| Conference II | Fouad Kandeel | 2024 Rachmiel Levine-Arthur Riggs Diabetes Research Symposium |
$20,000 |
| Conference II | Fouad Kandeel | 2016 Rachmiel Levine-Arthur Riggs Diabetes Research Symposium |
$10,000 |
| Clinical Trial Stage Projects | Elizabeth Budde | Phase I Study of Chimeric Antigen Receptor Engineered T Cells targeting CD33 for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia |
$11,983,547 |
| Clinical Trial Stage Projects | Dr. Angelo Manuel Almeida Cardoso Ph.D., MD | Evaluation of Safety and Feasibility of Cytomegalovirus-Specific, Anti-HIV Chimeric Antigen Receptor (CMV/HIV-CAR) T Cells in People with HIV |
$11,299,976 |
| Clinical Trial Stage Projects | Ryotaro Nakamura | Treatment of Severe Aplastic Anemia by induction of mixed chimerism using CD4+ T cell depleted haploidentical donor stem cell transplant |
$9,054,216 |
| Clinical Trial Stage Projects | Dr Jana Portnow | A Phase I Study of Multiple doses of NSC-Based Oncolytic Virotherapy Administered Intracerebrally to Patients with Recurrent High-Grade Gliomas |
$11,999,984 |
| Clinical Trial Stage Projects | Dr. Leo D Wang | Phase I Study of IL13Rα2-Targeting CAR T Cells After Lymphodepletion for Children with Refractory or Recurrent Malignant Brain Tumors |
$8,401,309 |
| Clinical Trial Stage Projects | Dr Saul J Priceman | A Phase I Study of Chimeric Antigen Receptor Engineered Stem/Memory T Cells for the Treatment of HER2-Positive Brain Metastases |
$9,015,149 |
| Clinical Trial Stage Projects | Dr. De-Fu Zeng | Treatment of sickle cell disease by induction of mixed chimerism and immune tolerance using CD4+ T-depleted haploidentical blood stem cell transplant |
$4,352,180 |
| Clinical Trial Stage Projects | Dr. Christine E. Brown | Phase I Study of Chimeric Antigen Receptor Engineered Central Memory T cells for the Treatment of Malignant Glioma |
$12,753,854 |
| Late Stage Preclinical Projects | Prof. Karen S Aboody M.D. | Neural stem cell delivered CRAd-S-pk7 oncolytic viro-immunotherapy for ovarian cancer |
$5,314,547 |
| Late Stage Preclinical Projects | Xiuli Wang | CMV-specific T cells expressing anti-HIV CAR and CMV vaccine boost as immunotherapy for HIV/AIDS |
$3,812,797 |
| Late Stage Preclinical Projects | Dr. Angelo Manuel Almeida Cardoso Ph.D., MD | Ex Vivo Gene Engineering of Blood Stem Cells for Enhanced Chemotherapy Efficacy in Glioblastoma Patients |
$3,684,259 |
| Alpha Stem Cell Clinics | Prof. John A. Zaia | The Innovation-Alpha Clinic for Cellular Therapies (I-ACT) – A Program for the Development and Delivery of Innovative Cell-based Treatments and Cures for Life-threatening Diseases. |
$8,416,531 |
| Tools and Technologies III | Joseph D Gold | Development of a scalable, practical, and transferable GMP-compliant suspension culture-based differentiation process for cardiomyocyte production from human embryonic stem cells. |
$891,518 |
| Conference | Fouad Kandeel | 15th Annual Rachmiel Levine Diabetes and Obesity Symposium |
$20,000 |
| Conference | Richard Jove | Innovative Partnerships: Bringing Stem Cell Discoveries to the Clinic |
$14,994 |
| Conference | Richard Jove | Innovation and Translational Stem Cell Therapy for Diabetes and Neurological Diseases: Paving the way for real life solutions |
$14,878 |
| Conference | Richard Jove | New Approaches in Cell Based Therapies |
$20,000 |
| Conference | Fouad R Kandeel | 2012 Rachmiel Levine Diabetes and Obesity Symposium: Advances in Diabetes Research |
$15,000 |
| Conference | Fouad R Kandeel | 2011 Rachmiel Levine Diabetes and Obesity Symposium: Advances in Diabetes Research |
$15,000 |
| Conference | Fouad R Kandeel | 2013 Rachmiel Diabetes and Obesity Levine Symposium – Advances in Diabetes Research |
$27,750 |
| Conference | Fouad R Kandeel | 2009 Rachmiel Levine Diabetes and Obesity Symposium: Advances in Diabetes Biology, Immunology and Cell Therapy |
$15,000 |
| Strategic Partnership III Track A | Prof. John A. Zaia | A Phase I, Open-Label Study To Assess The Safety, Feasibility and Engraftment of Zinc Finger Nucleases (ZFN) CCR5 Modified Autologous CD34+ Hematopoietic Stem/Progenitor Cells (SB-728MR-HSPC) with Escalating Doses of Busulfan In HIV-1 (R5) Infected Sub… |
$5,583,438 |
| Disease Team Planning | Dr. Michael E. Barish Ph, D. | Genetically-modified neural stem cells for treatment of high-grade glioma |
$55,000 |
| Creativity Awards | Dr. Paul M. Salvaterra | Creativity Award Program in Stem Cell Biology for California High School Students |
$260,825 |
| Basic Biology IV | Dr. Yanhong Shi Ph.D. | Modeling Alexander disease using patient-specific induced pluripotent stem cells |
$1,366,656 |
| Early Translational III | Dr. Stephen J Forman | Targeting glioma cancer stem cells with receptor-engineered self-renewing memory T cells |
$5,215,447 |
| Research Training II | Dr. Michael E. Barish Ph, D. | City of Hope Research Training Program in Stem Cell Biology |
$2,197,782 |
| Basic Biology III | Dr. Jiing-Kuan Yee Ph.D. | Use of human iPS cells to study spinal muscular atrophy |
$1,268,868 |
| Early Translational II | Dr. Yanhong Shi Ph.D. | Developing a therapeutic candidate for Canavan disease using induced pluripotent stem cell |
$1,835,983 |
| Early Translational II | Dr. David Louis DiGiusto | Development of RNA-based approaches to stem cell gene therapy for HIV |
$3,097,160 |
| New Faculty I | Dr. Tiziano Barberi | Skeletal muscle development from hESC and its in vivo applications in animal models of muscular dystrophy |
$131,840 |
| Tools and Technologies I | Joseph Shi Gold | Development of Suspension Adaptation, Scale-up cGMP Banking and Cell Characterization Technologies for hESC Lines |
$882,929 |
| SEED Grant | Dr. Timothy R. O’Connor | Sources of Genetic Instability in Human Embryonic Stem Cells. |
$327,311 |
| Disease Team Research I | Prof. Karen S Aboody M.D. | Stem Cell-mediated Therapy for High-grade Glioma: Toward Phase I-II Clinical Trials |
$17,890,623 |
| Disease Team Research I | Prof. John A. Zaia | ZINC FINGER NUCLEASE-BASED STEM CELL THERAPY FOR AIDS |
$14,536,969 |
